Biogen says U.S. FTC, SEC probing Alzheimer's disease drug

cafead

Administrator
Staff member
  • cafead   Feb 07, 2022 at 11:42: PM
via The U.S. Federal Trade Commission and the U.S. Securities and Exchange Commission have asked Biogen Inc (BIIB.O) to provide information on the approval and marketing of its new Alzheimer's disease treatment, Aduhelm, the drugmaker disclosed in a filing.

article source